

<https://helda.helsinki.fi>

Gastrointestinal Symptoms and Dopamine Transporter Asymmetry in Early Parkinson's Disease

Murtomäki, Kirsi

2022-06

Murtomäki , K , Mertsalmi , T , Jaakkola , E , Mäkinen , E , Levo , R , Nojonen , T , Eklund , M , Nuutila , S , Lindholm , K , Pekkonen , E , Joutsa , J , Nojonen , T , Ihalainen , T , Kaasinen , V & Scheperjans , F 2022 , ' Gastrointestinal Symptoms and Dopamine Transporter Asymmetry in Early Parkinson's Disease ' , *Movement Disorders* , vol. 37 , no. 6 , pp. 1284-1289 . <https://doi.org/10.1002/mds.28986>

<http://hdl.handle.net/10138/346095>

<https://doi.org/10.1002/mds.28986>

cc_by

publishedVersion

Downloaded from Helda, University of Helsinki institutional repository.

This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

Gastrointestinal Symptoms and Dopamine Transporter Asymmetry in Early Parkinson's Disease

Kirsi Murtomäki, MD,¹  Tuomas Mertsalmi, MD,¹
 Elina Jaakkola, MD, PhD,²  Elina Mäkinen, MD, PhD,^{1,2} 
 Reeta Levo, RN,¹ Tanja Nojonen, RN,¹
 Mikael Eklund, BM,^{2,3,4} Simo Nuutila, BM,² 
 Kari Lindholm, RN,² Eero Pekkonen, MD, PhD,¹
 Juho Joutsa, MD, PhD,^{2,3,4} Tommi Noponen, PhD,⁵
 Toni Ihalainen, PhD,⁶ Valtteri Kaasinen, MD, PhD,²  and
 Filip Scheperjans, MD, PhD^{1*} 

¹Department of Neurology, Helsinki University Hospital, and Clinicum, University of Helsinki, Helsinki, Finland ²Clinical Neurosciences, University of Turku, and Neurocenter, Turku University Hospital, Turku, Finland ³Turku PET Centre, Turku University Hospital, Turku, Finland ⁴Turku Brain and Mind Center, University of Turku, Turku, Finland ⁵Department of Clinical Physiology and Nuclear Medicine, Department of Medical Physics, Turku University Hospital, Turku, Finland ⁶HUS Medical Imaging Center, Clinical Physiology and Nuclear Medicine, University of Helsinki and Helsinki University Hospital, Helsinki, Finland

ABSTRACT: Background: The neurophysiological correlates of gastrointestinal symptoms (GISs) in Parkinson's disease (PD) are not well understood. It has been proposed that in patients with a gastrointestinal origin of PD dopaminergic neurodegeneration would be more symmetric.

Objectives: The aim is to assess the associations between GISs and asymmetry of nigrostriatal dopaminergic neurodegeneration in PD.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

*Correspondence to: Dr. Filip Scheperjans, Department of Neurology, Helsinki University Hospital, and Clinicum, University of Helsinki, POB 700, FIN-00029 HUS, Helsinki, Finland; E-mail: filip.scheperjans@hus.fi

Relevant conflicts of interest/financial disclosures: None.

Funding agencies: The Academy of Finland (295724 and 310835), the Hospital District of Helsinki and Uusimaa (UAK1014004, UAK1014005, and TYH2018224), the Finnish Medical Foundation, the Finnish Parkinson Foundation, the Turku University Hospital (VTR-funds), the Päivikki and Sakari Sohlberg Foundation, The Finnish Alcohol Research Foundation, the Turku University Foundation/Kosti Hämmärö-fund, and the Maire Taponen Foundation.

Received: 4 December 2021; **Revised:** 1 February 2022; **Accepted:** 13 February 2022

Published online 11 March 2022 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.28986

Methods: Ninety PD patients were assessed using motor and GIS scales and ¹²³I-FP-CIT SPECT. We calculated the asymmetry index and the predominant side of motor symptoms and dopamine transporter (DAT) imaging defect and assessed their association with GISs.

Results: There were no significant differences in GISs between symmetric and asymmetric dopaminergic defect. Left predominant defect was related to more GIS and higher constipation scores.

Conclusions: GISs were associated with left predominant reduction in putaminal DAT binding but not asymmetry per se. It remains open whether left-sided DAT deficit is related to more pronounced GI involvement or symptom perception in PD. © 2022 The Authors. *Movement Disorders* published by Wiley Periodicals LLC on behalf of International Parkinson Movement Disorder Society.

Key Words: Parkinson's disease, gastrointestinal symptoms, dopamine transporter

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor manifestations.¹ Typically, motor symptoms emerge unilaterally or asymmetrically.² A considerable subgroup of patients suffer from gastrointestinal symptoms (GISs) such as functional constipation (FC) or irritable bowel syndrome (IBS),³⁻⁵ and autopsy studies have shown α -synuclein pathology throughout the spinal cord and peripheral nervous systems.⁶

Recently, an α -synuclein origin site and connectome (SOC) model has been suggested, dividing PD into brain-first and body-first subtypes.⁷ In the brain-first subtype, the α -synuclein pathology spreads mainly unilaterally, whereas in the body-first subtype, pathology is more symmetric due to the bilateral spreading of α -synuclein via the vagus nerve.

Dopamine transporter (DAT) imaging with single-photon emission computerized tomography (SPECT) is an in vivo biomarker of nigrostriatal neuron loss. The correlation between the motor symptoms and the striatal DAT binding is well recognized; however, the relation between nonmotor symptoms and DAT binding has been investigated in only a few studies.^{8,9} In two studies on the Parkinson's Progressive Markers Initiative cohort, nonmotor symptoms have been associated with reduced striatal DAT binding.^{10,11}

We hypothesized that in early-stage PD patients, less asymmetric DAT deficit is associated with more GISs.

The study was approved by the Ethics Committee of the Turku University Hospital and was conducted according to the principles of the Declaration of Helsinki. All participants provided written informed consent.

Patients and Methods

Ninety PD patients were imaged using ^{123}I -FP-CIT SPECT because of parkinsonism or tremor in 2015–2019 at Helsinki and Turku University Hospitals (NMDAT study, ClinicalTrials.gov identifier NCT02650843). See the supplement for inclusion and exclusion criteria.

SPECT Imaging and Data Analysis

See the supplement for technical details of SPECT imaging. Specific DAT binding was calculated from striatal subregions (caudate, anterior putamen, and

TABLE 1 Basic characteristics of PD patients

Characteristics	PD
Number of patients	90
Age, mean \pm SD	65.29 \pm 9.97
Sex: male, n (%)	46 (51.1)
Handedness: right, n (%)	85 (94.4)
MMSE, ¹⁴ mean \pm SD	27.51 \pm 1.86
Motor symptoms in months, mean \pm SD	28.92 \pm 31.09
Hoehn and Yahr (H&Y) score, mean \pm SD	1.99 \pm 0.71 H&Y 1, N (%)21 (23.3)
H&Y 2, N (%)	51 (56.7)
H&Y 3, N (%)	16 (17.8)
H&Y 4, N (%)	2 (2.2)
MDS-UPDRS III total score, ¹⁵ mean \pm SD	34.72 \pm 13.57
MDS-UPDRS III tremor score, ¹³ mean \pm SD	4.60 \pm 3.27
MDS-UPDRS III bradykinesia-rigidity score, ¹³ mean \pm SD	19.08 \pm 9.39
NMSS total score, ¹⁶ mean \pm SD	41.68 \pm 31.72
Dream enactment (possible RBD), ¹⁷ N (%)	24 (26.7)
Functional gastrointestinal disorders, N (%)	32 (35.6)
IBS, n (%)	17 (18.9)
Functional dyspepsia, n (%)	14 (15.5)
Functional constipation, n (%)	4 (4.4)
Functional bloating, n (%)	3 (3.3)
Functional diarrhea, n (%)	1 (1.1)
Rome III constipation subscore, ¹⁸ mean \pm SD	5.96 \pm 5.13
Wexner total score, ¹⁹ mean \pm SD	5.04 \pm 4.05
CSI total score, ²⁰ mean \pm SD	15.20 \pm 11.30
NMSS constipation score, mean \pm SD	1.66 \pm 3.33
Mean putamen absolute value, mean \pm SD	0.14 \pm 0.10
Patients with dopaminergic medication, N (%)	25 (28.1)
Mean levodopa equivalent daily dose, mean \pm SD (range)	82.27 \pm 155.36 (0–600)

Wexner and CSI are constipation questionnaires. Rome III assesses functional gastrointestinal disorders.

Abbreviations: PD, Parkinson's disease; SD, standard deviation; MMSE, Mini-Mental State Examination; N, number of patients; MDS-UPDRS III, MDS Unified Parkinson's Disease Rating Scale, Part III; NMSS, Non-Motor Symptoms Scale; IBS, irritable bowel syndrome; CSI, Constipation Severity Instrument.

posterior putamen) using region-to-occipital cortex ratio with BRASS software (Table S3).¹²

The limit for an abnormal scan was more than two standard deviations below the reference mean in any of the six analyzed regions.

Mean putamen DAT binding was calculated for both sides as mean putamen = (anterior putamen SBR + posterior putamen SBR)/2.

Mean putamen asymmetry index (AI) in DAT uptake was then calculated as $AI = (\text{putamen}_{\text{highest}} - \text{putamen}_{\text{lowest}}) / (\text{putamen}_{\text{highest}} + \text{putamen}_{\text{lowest}})$. AI > 0.05 was considered as significantly asymmetric reduction in DAT binding.¹³

Clinical Features

Assessments are summarized in Table 1. The MDS-UPDRS, Part III, total score and subscores for tremor, bradykinesia, and rigidity were separately calculated

for both sides¹³ (see Appendix S1). AI was calculated for all these lateralized scores.¹³ Significant asymmetry was defined as AI > 0.3.

We used Rome III criteria for the identification of functional gastrointestinal disorders (FGIDs): IBS, FC, functional diarrhea, functional dyspepsia, and functional bloating.

Imaging Asymmetry and Clinical Symptoms

Based on the motor symptoms' AIs, 50 (55.6%) patients had predominantly symmetric, 20 (22.2%) predominantly right-sided, and 20 (22.2%) predominantly left-sided motor symptoms at the time of imaging. In many of the previous studies, the laterality has been analyzed based on motor symptoms, but we also utilized dopamine imaging data. The motor symptoms AI correlated with the imaging AI best for mean putamen (Figure S1).

TABLE 2 . PD patients divided into asymmetric and symmetric groups based on mean putamen asymmetry index

	Mean putamen imaging deficiency		P-value
	Asymmetric (N = 72)	Symmetric (N = 18)	
Patients, N (%)	72 (80.0)	18 (20.0)	
Age, mean ± SD	64.62 ± 9.94	68.78 ± 9.54	0.082
Sex: male, N (%)	35 (48.6)	11 (61.1)	0.34
MMSE, mean ± SD	27.39 ± 1.92	28.00 ± 1.57	0.26
Motor symptoms in months, mean ± SD	27.64 ± 25.67	34.06 ± 47.69	0.60
Nonmotor symptoms in months, mean ± SD	136.83 ± 173.18	102.33 ± 182.06	0.071
Hoehn & Yahr, mean ± SD	1.94 ± 0.75	2.17 ± 0.51	0.16
MDS-UPDRS III total score, mean ± SD	33.54 ± 13.46	39.44 ± 13.34	0.099
MDS-UPDRS III tremor score, mean ± SD	4.42 ± 3.11	5.33 ± 3.85	0.41
MDS-UPDRS III bradykinesia-rigidity score, mean ± SD	18.42 ± 9.36	21.72 ± 9.30	0.17
NMSS total score, mean ± SD	44.13 ± 33.57	31.89 ± 20.82	0.22
Dream enactment (possible RBD), N (%)	18 (25.0)	6 (33.3)	0.70
Functional gastrointestinal disorders, N (%)	28 (38.9)	4 (22.2)	0.19
IBS, N (%)	16 (22.2)	1 (5.6)	0.11
Dyspepsia, N (%)	10 (13.9)	2 (22.2)	0.38
Rome III constipation subscore, mean ± SD	6.13 ± 5.55	5.28 ± 2.97	0.94
Wexner sum, mean ± SD (N = 88)	5.38 ± 4.31	3.68 ± 2.46	0.29
CSI total score, mean ± SD (N = 89)	15.13 ± 11.80	15.47 ± 9.33	0.62
NMSS constipation score, mean ± SD	1.61 ± 0.39	1.83 ± 0.81	0.47

Wexner and CSI are constipation questionnaires. Rome III assesses functional gastrointestinal disorders.

Abbreviations: PD, Parkinson's disease; SD, standard deviation; N, number of patients; MMSE, Mini-Mental State Examination; MDS-UPDRS III, MDS Unified Parkinson's Disease Rating Scale, Part III; NMSS, Non-Motor Symptoms Scale; IBS, irritable bowel syndrome; CSI, Constipation Severity Instrument.

Statistical Analyses

All the analyses were performed using IBM SPSS Statistics version 25 (see Appendix S1 for details).

Results

GISs in PD Patients

Basic cohort characteristics are summarized in Table 1 and Table S1. Thirty-two patients (35.6%) fulfilled the criteria for at least one FGID.

Asymmetry Indexes and GISs

In mean putamen, 72 (80.0%) patients had asymmetric and 18 (20.0%) symmetric reduction in DAT binding. The majority of the patients (90%) reported asymmetric and 10% symmetric onset of motor symptoms. Degree of asymmetry of mean putamen DAT binding showed no statistically significant association with any clinical measure (Table 2).

When compared to patients with symmetric or right-predominant reduction in mean putamen DAT binding, FGIDs (in particular IBS) were significantly more common and Wexner constipation scores higher in patients with left-predominant reduction (Table S2; Figure S2).

Discussion

The aim of this study was to elucidate the association between nigrostriatal DAT binding asymmetry and GISs in PD. Falsifying our initial hypothesis, more symmetrical binding was not associated with increased GISs.⁷ Instead, FGIDs and symptoms of constipation were associated with left-predominant putaminal reduction in DAT binding. Our results suggest that not asymmetry per se but rather left-predominant defect is associated with reported GISs in PD.

The proportion of PD patients fulfilling the criteria for IBS (18.9%, $n = 17$) observed in this study is in line with previous findings in Finnish (24.3%) and Japanese (27.1%) populations.^{5,21} On the contrary, the prevalence of FC (4.4%) was quite low compared to earlier observations in the Finnish and Japanese cohorts (12.2% and 17.1%, respectively). A previous Korean study reported higher prevalence of FC (74.3%) and lower prevalence of IBS (2.9%) in PD, whereas the prevalence of functional dyspepsia (14.3%) was comparable to our results.²²

Previous studies have suggested a relation between the laterality of dopaminergic neurodegeneration and nonmotor symptoms in PD. In contrast to our study, the study by Deursen and colleagues showed that autonomic symptoms were related to lower ¹²³I-FP-CIT binding ratios in the right caudate nucleus and mainly driven by gastrointestinal [Scales for Outcomes in

Parkinson's Disease—Autonomic (SCOPA-AUT) score] and cardiovascular dysfunction.²³ Differences between the results could be explained by the patient population. Deursen's study had a larger sample size (310 vs. 90), the mean levodopa equivalent daily dose was higher (136.70 vs. 82.27 mg), and the disease duration was longer (3.68 vs. 2.5 years) compared to our study. The SCOPA-AUT has only seven questions on GISs, whereas the Rome III has 27, assessing GISs more widely. Further, in Miyamoto's study, right-handed idiopathic rapid eye movement sleep behavior disorder (iRBD) patients had faster degeneration in the left hemisphere.²⁴ A recent study found a relation between left-hemispheric dopaminergic denervation and cognitive impairment in PD.²⁵ Further, previous studies have suggested laterality of PD motor symptoms to be associated with nonmotor symptoms with mixed results.

Psychosis has been associated with right-predominant motor symptoms.⁹ On the contrary, PD patients with right-predominant motor dysfunction appear to exhibit greater cognitive impairment.^{26,27} Thus, lateralization may influence nonmotor symptoms.

The SOC model posits that α -synuclein pathology is the core feature in PD pathogenesis. The anatomical location of the first pathogenic α -synuclein is important, and the neural connectome also plays a crucial role in determining how pathological α -synuclein propagates through the nervous system.⁷ If the α -synuclein pathology starts from the gut and slowly propagates caudo-rostrally through the vagal nerves, which do not show strong lateralization, to the dorsal motor nuclei of vagus and then bilaterally to the brainstem, we would expect predominantly symmetric DAT binding defect. A recent article by Van Den Berge and Ulusoy discussed that animal models also support the SOC model, with more symmetric α -synuclein spreading after peripheral initiation of pathology as compared to stronger asymmetry after intracerebral initiation.²⁸ Environmental toxins in both animals and humans mostly cause bilateral parkinsonism.²⁷ Recent pathological evidence supports the existence of two patterns of α -synuclein pathology with caudo-rostral or amygdala-based progression.²⁹ A cortical pathogenic theory postulates the existence of top-down corticostriatal processes that could drive asymmetric retrograde nigrostriatal degeneration.³⁰ Therefore, multiple mechanisms may govern the degree of asymmetry of PD pathology and symptoms.

Although our results did not confirm a relation between subjective GISs and stronger symmetry of dopaminergic neurodegeneration, our results do not necessarily argue against the SOC model. The GI tract is regulated by the local nervous system and the vagal nerve. Furthermore, the information spreads through the vagal nerve to the striatum but also wider in the central nervous system. Consequently, the correlation between

subjective GISs and objective dysfunction has been far from optimal.^{31,32} Also, abnormal gut motility, visceral hypersensitivity, inflammation, or altered bacterial flora may influence the GISs. In addition, female patients tend to have more GISs than male patients, but there were no significant differences in our study.

Overall, patients' symptom experience is a combination of different mechanisms, and it cannot be directly inferred that patients with more severe subjective GISs have more gut pathology.

The main strength of this study is that the laterality of PD pathology was assessed using ¹²³I-FP-CIT SPECT and not only by the distribution of motor symptoms. However, the definition of symmetrically reduced dopaminergic activity is artificial. We chose a previously used definition of AI value between -0.05 and 0.05 , and it is possible that other cutoff values would produce different results.¹³

Another strength of this study is that the diagnosis of PD was confirmed using the ¹²³I-FP-CIT SPECT, and patients were followed to further minimize the probability of false PD diagnosis (the mean follow-up time being 30 months).

Given that patients were sent to imaging for diagnosis, most of them had early-stage symptoms without long use of dopaminergic medication or were drug-naive patients. Nevertheless, the average time since motor symptom onset in our cohort was 29 months and, nonsignificantly, longer in symmetric (34 months) than in asymmetric (27.6 months) patients. This is longer than in previous imaging studies of RBD-positive (17 months) and RBD-negative (21.5 and 24 months, respectively) PD patients, and we cannot exclude that diminishing of asymmetry during disease progression influenced our results.^{33,34} It is also possible that in our cohort there was clinical uncertainty about PD diagnosis, prompting referral to ¹²³I-FP-CIT SPECT imaging to confirm the diagnosis and leading to selection bias. These PD patients might thus differ from the general PD population in terms of the underlying etiologic factors, and results cannot necessarily be generalized to the entire PD population.

One limitation in our study is that the GISs are based only on questionnaires. No objective functional gastrointestinal investigations were carried out.³¹ However, in a study on PD patients with constipation and patients with FC, the patients had severe functional dysmotility of the colon and rectum, based on transit test and manometry,³² supporting using the Rome questionnaire.

In conclusion, GIS burden was not associated with the degree of symmetry of DAT defect but rather with left-sided DAT decrease. Further studies using objective biomarkers to assess GI pathology and dysfunction are needed to establish whether left-sided DAT deficit is

related to more pronounced GI involvement or rather symptom perception in PD. ■

Acknowledgments: We thank Drs. Antti Loimaala and Sorjo Mätzke as well as the teams of the nuclear medicine departments in Meilahti and Jorvi hospitals for allowing us to recruit and study patients in their departments and supporting us throughout the study. We thank all the participants in the study.

Data Availability Statement

Data available on request due to privacy/ethical restrictions

References

1. Pirker W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? *Mov Disord* 2003;18(S7):43–51.
2. Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-ES recommendations for the diagnosis of parkinson's disease. *Eur J Neurol* 2013;20:16–34.
3. Poirier AA, Aubé B, Côté M, Morin N, Di Paolo T, Soulet D. Gastrointestinal dysfunctions in Parkinson's disease: symptoms and treatments. *Parkinsons Dis* 2016;23:6762528.
4. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. *Neurology* 2001;57(3):456–462.
5. Mertsalmi TH, Aho VTE, Pereira PAB, et al. More than constipation: bowel symptoms in parkinson's disease and their connection to gut microbiota. *Eur J Neurol* 2017;24:1375–1383.
6. Beach TG, Adler CH, Sue LI, et al. Multi-organ distribution of phosphorylated α -synuclein histopathology in subjects with Lewy body disorders NIH public access author manuscript. *Acta Neuropathol* 2010;119(6):689–702.
7. Borghammer P. The α -synuclein origin and connectome model (SOC model) of parkinson's disease: explaining motor asymmetry, non-motor phenotypes, and cognitive decline. *J Parkinsons Dis* 2021;11(2):455–474.
8. Cooper CA, Mikos AE, Wood MF, et al. Does laterality of motor impairment tell us something about cognition in Parkinson disease? *Parkinsonism Relat Disord* 2009;15(4):315–317.
9. Cubo E, Martínez Martín P, Martín-González JA, Rodríguez-Blázquez C, Kulisevsky J. Motor laterality asymmetry and non-motor symptoms in Parkinson's disease. *Mov Disord* 2010;25(1):70–75.
10. Hinkle JT, Perepezko K, Mills KA, et al. Dopamine transporter availability reflects gastrointestinal dysautonomia in early parkinson disease. *Parkinsonism Relat Disord* 2018;55:8
11. Kim R, Jun J. Association of autonomic symptoms with presynaptic striatal dopamine depletion in drug-naive parkinson's disease: an analysis of the PPMI data. *Auton Neurosci* 2019;216:59–62.
12. Kaasinen V, Kinoshita M, Joutsa J, Seppänen M, Noponen T. Differences in striatal dopamine transporter density between tremor dominant and non-tremor parkinson's disease. *Eur J Nucl Med Mol Imaging* 2014;41(10):1931–1937.
13. Kaasinen V. Ipsilateral deficits of dopaminergic neurotransmission in parkinson's disease. *Ann Clin Transl Neurol* 2016;3(1):21–26.
14. Folstein MF, Folstein SE, McHugh PR. "MINI-MENTAL STATE": a practical method for grading the cognitive STATE of patients for the clinician. *J Psychiatr Res* 1975;12:189–198.
15. Goetz CG, Tilley BC, Shaftman SR, et al. Movement disorder society-sponsored revision of the unified parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. *Mov Disord* 2008;23(15):2129–2170.
16. Chaudhuri KR, Martínez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for parkinson's

disease: results from an international pilot study. *Mov Disord* 2007; 22(13):1901–1911.

17. Postuma RB, Arnulf I, Høgl B, et al. A single-question screen for rapid eye movement sleep behavior disorder: a multicenter validation study. *Mov Disord* 2012;27(7):913–916.
18. Drossman DA, Dumitrascu DL. Rome III criteria rome III: new standard for functional gastrointestinal disorders. *J Gastrointest Liver Dis* 2006;15(3):237–241.
19. Agachan F, Chen T, Pfeifer J, Reissman P, Wexner SD. A constipation scoring system to simplify evaluation and management of constipated patients. *Dis Colon Rectum* 1996;39(6):681–685.
20. Varma M, Varma M, Wang J, et al. The constipation severity instrument: a validated measure. *Dis Colon Rectum* 2008;51(2):162–172.
21. Mishima T, Fukae J, Fujioka S, Inoue K, Tsuboi Y. The prevalence of constipation and irritable bowel syndrome in parkinson's disease patients according to rome III diagnostic criteria. *J Parkinsons Dis* 2017;7(2):353–357.
22. Lee HJ, Jung KW, Chung SJ, et al. Relation of enteric α -synuclein to gastrointestinal dysfunction in patients with parkinson's disease and in neurologically intact subjects. *J Neurogastroenterol Motil* 2018; 24(3):469–478.
23. van Deursen DN, van den Heuvel OA, Booij J, Berendse HW, Vriend C. Autonomic failure in parkinson's disease is associated with striatal dopamine deficiencies. *J Neurol* 2020;267(7):1922–1930.
24. Miyamoto T, Akaiwa Y, Numahata K, Yoshizawa K, Sairenchi T, Miyamoto M. Striatal dopamine transporter degeneration in right-handed REM sleep behavior disorder patients progresses faster in the left hemisphere. *Parkinsons Relat Disord* 2022;95:107–112.
25. Fiorenzato E, Antonini A, Bisiacchi P, Weis L, Biundo R. Asymmetric dopamine transporter loss affects cognitive and motor progression in Parkinson's disease. *Mov Disord* 2021;36(10):2303–2313.
26. Hanna-Pladdy B, Pahwa R, Lyons KE. Paradoxical effect of dopamine medication on cognition in parkinson's disease: relationship to side of motor onset. *J Int Neuropsychol Soc* 2015;21(4):259–270.
27. Riederer P, Jellinger KA, Kolber PP, Hipp G, Sian-Hülsmann J, Krüger RR. Lateralisation in parkinson disease. *Cell Tissue Res* 2018;373(1):297–312.
28. Van Den Berge N, Ulusoy A. Animal models of brain-first and body-first Parkinson's disease. *Neurobiol Dis* 2022;163:105599. <https://doi.org/10.1016/j.nbd.2021.105599>.
29. Raunio A, Kaivola K, Tuimala J, et al. Lewy-related pathology exhibits two anatomically and genetically distinct progression patterns: a population-based study of Finns aged 85+. *Acta Neuropathol* 2019;138:771–782.
30. Foffani G, Obeso J. A cortical pathogenic theory of parkinson's disease. *Neuron* 2018;99(6):1116–1128.
31. Knudsen K, Fedorova TD, Bekker AC, et al. Objective colonic dysfunction is far more prevalent than subjective constipation in parkinson's disease: a colon transit and volume study. *J Parkinsons Dis* 2017;7(2):359–367.
32. Zhang M, Yang S, Li X, et al. Study on the characteristics of intestinal motility of constipation in patients with Parkinson's disease. *World J Gastroenterol* 2021;27(11):1055–1063.
33. Horsager J, Andersen KB, Knudsen K, et al. Brain-first versus body-first Parkinson's disease: a multimodal imaging case-control study. *Brain* 2020;143:3077–3088.
34. Knudsen K, Fedorova TD, Horsager J, et al. Asymmetric dopaminergic dysfunction in brain- first versus body-first Parkinson's disease subtypes. *J Parkinsons Dis* 2021;11(4): 1677–1687.

Attitudes Toward Telehealth Services Among People Living With Parkinson's Disease: A Survey Study

Yaqian Xu, MD, MPH,¹ Megan P. Feeney, MPH,² Matthew Surface, BA,^{3,4} Dan Novak, PhD, MBA,² Michelle S. Troche, PhD, CCC-SLP,⁵ James C. Beck, PhD,² and Roy N. Alcalay, MD, MS^{3,6*}

¹Department of Psychiatry, Columbia University Irving Medical Center, New York, New York, USA ²Parkinson's Foundation, New York, New York, USA ³Department of Neurology, Columbia University Irving Medical Center, New York, New York, USA ⁴The Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA ⁵Department of Biobehavioral Sciences, Teachers College, Columbia University, New York, New York, USA ⁶Movement Disorders Division, Neurological Institute, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

ABSTRACT: Background: Telehealth has been widely adopted in providing Parkinson's disease care during the coronavirus disease 2019 pandemic.

Objective: The aim of this study was to survey people living with Parkinson's disease (PwPD) about their attitudes toward and utilization of telehealth services.

Methods: A survey was administered to PwPD via Parkinson's Foundation and Columbia University mailing lists.

Results: Of 1,163 responses, 944 complete responses were analyzed. Telehealth awareness was 90.2% (850/942), and utilization was 82.8% (780/942). More than 40% of PwPD were equally or more satisfied with telehealth compared with in-person visits in all types of services used. The highest satisfaction was observed in speech-language pathology appointments (78.8%, 52/66) followed by mental health services (69.2%, 95/137).

Conclusions: In selected circumstances and indications, such as speech-language pathology and mental health services, telehealth may be a useful tool in the care of PwPD beyond the coronavirus disease 2019

Supporting Data

Additional Supporting Information may be found in the online version of this article at the publisher's web-site.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

*Correspondence to: Dr. Roy N. Alcalay, Department of Neurology, Columbia University Irving Medical Center, 710 W. 168th St., New York, NY 10032, USA; E-mail: rna2104@cumc.columbia.edu

Relevant conflicts of interest/financial disclosures: Nothing to report.

Received: 28 January 2022; **Revised:** 24 February 2022; **Accepted:** 28 February 2022

Published online 26 March 2022 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.28990